Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients
- PMID: 21744990
- DOI: 10.4149/neo_2011_05_377
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients
Abstract
Urokinase (uPA) plays an essential role in the activation of plasminogen to plasmin, and together with its receptor (uPAR), tissue activator (tPA) and urokinase inhibitors (PAI 1, PAI 2, PAI 3 and protease nexin) forms the plasminogen activator system (PAS), a component of metastatic cascade importantly contributing to the invasive growth and angiogenesis of malignant tumours. In our project we examined the expression of uPA, uPAR, PAI 1 and PAI 2 in tumor tissue and we also studied the plasma levels of PAI 1 before and after the initiation of therapy in patients with colorectal carcinoma in relationship to grade of tumor and the treatment response. In our prospective evaluation we included 80 patients treated for adenocarcinoma of the colon and rectum. Analysis of collected data revealed statistically significant evidence of a relationship between the level of PAI 1 in plasma before treatment and grade of the tumor, which increases with tumor grade (p=0.025). We demonstrated that there exists a statistically significant relationship between the expression of PAI 2 (p<0.001) and uPAR (p=0.031) and grade of tumor. We also confirmed a statistically significant relationship between soluble levels of PAI 1 before treatment and therapeutic response (p=0.021). In our group of patients the expression of uPA, uPAR, PAI 1 and 2 in tumor tissue in relation to response to treatment was also assessed. Our results suggest that the greater expression of these parameters in tumor tissue is linked to a worse response to therapy. In conclusion, PAS factors help as a prognostic indicators and could also act as a predictive factor in colorectal carcinoma.
Similar articles
-
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.Cancer. 1999 Dec 15;86(12):2602-11. doi: 10.1002/(sici)1097-0142(19991215)86:12<2602::aid-cncr4>3.0.co;2-s. Cancer. 1999. PMID: 10594855
-
Plasminogen Activation System in Rectal Adenocarcinoma.Anticancer Res. 2015 Nov;35(11):6009-15. Anticancer Res. 2015. PMID: 26504024
-
Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.Hepatogastroenterology. 2011 Nov-Dec;58(112):1918-25. doi: 10.5754/hge10232. Hepatogastroenterology. 2011. PMID: 22234062
-
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.Oncotarget. 2017 Apr 4;8(14):23099-23109. doi: 10.18632/oncotarget.15485. Oncotarget. 2017. PMID: 28416743 Free PMC article.
-
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.Clin Biochem. 2004 Jul;37(7):541-8. doi: 10.1016/j.clinbiochem.2004.05.013. Clin Biochem. 2004. PMID: 15234235 Review.
Cited by
-
Cathepsin V Mediates the Tazarotene-induced Gene 1-induced Reduction in Invasion in Colorectal Cancer Cells.Cell Biochem Biophys. 2020 Dec;78(4):483-494. doi: 10.1007/s12013-020-00940-3. Epub 2020 Sep 12. Cell Biochem Biophys. 2020. PMID: 32918681
-
Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.Transl Oncol. 2014 Apr;7(2):174-187.e5. doi: 10.1016/j.tranon.2014.02.002. Epub 2014 Mar 4. Transl Oncol. 2014. PMID: 24913672 Free PMC article.
-
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.Biomed Res Int. 2015;2015:392862. doi: 10.1155/2015/392862. Epub 2015 Mar 26. Biomed Res Int. 2015. PMID: 25883959 Free PMC article.
-
In silico research of coagulation- and fibrinolysis-related genes for predicting prognosis of clear cell renal cell carcinoma.Transl Androl Urol. 2025 Feb 28;14(2):307-324. doi: 10.21037/tau-24-483. Epub 2025 Feb 25. Transl Androl Urol. 2025. PMID: 40114841 Free PMC article.
-
Novel Hypoxia-Associated Gene Signature Depicts Tumor Immune Microenvironment and Predicts Prognosis of Colon Cancer Patients.Front Genet. 2022 Jun 6;13:901734. doi: 10.3389/fgene.2022.901734. eCollection 2022. Front Genet. 2022. PMID: 35734431 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous